BR112021023881A2 - Métodos e composições para tratamento de epilepsia - Google Patents

Métodos e composições para tratamento de epilepsia

Info

Publication number
BR112021023881A2
BR112021023881A2 BR112021023881A BR112021023881A BR112021023881A2 BR 112021023881 A2 BR112021023881 A2 BR 112021023881A2 BR 112021023881 A BR112021023881 A BR 112021023881A BR 112021023881 A BR112021023881 A BR 112021023881A BR 112021023881 A2 BR112021023881 A2 BR 112021023881A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
treating epilepsy
ht2b
epilepsy
Prior art date
Application number
BR112021023881A
Other languages
English (en)
Inventor
R Renslo Adam
L Griffin Aliesha
Priyadarshini Jaishankar
C Baraban Scott
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR112021023881A2 publication Critical patent/BR112021023881A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/03—Animals modified by random mutagenesis, e.g. using ENU, chemicals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/40—Fish
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2857—Seizure disorders; Epilepsy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

métodos e composições para tratamento de epilepsia. são fornecidos, entre outras coisas, métodos e composições para o tratamento de epilepsia. em um aspecto, é fornecido no presente documento um método para selecionar um composto para tratar epilepsia, em que o dito método inclui, colocar um composto de teste em contato com o receptor 5-hidroxitriptamina-2b (5-ht2b), e medir a atividade agonística de 5-ht2b do composto de teste. em outro aspecto, é fornecido neste documento um método para tratar uma epilepsia em um sujeito em necessidade do mesmo. o método inclui administrar ao dito sujeito uma quantidade eficaz de um agonista receptor específico de 5-ht2b.
BR112021023881A 2019-05-29 2020-05-28 Métodos e composições para tratamento de epilepsia BR112021023881A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962853971P 2019-05-29 2019-05-29
PCT/US2020/034981 WO2020243349A1 (en) 2019-05-29 2020-05-28 Methods and compositions for treating epilepsy

Publications (1)

Publication Number Publication Date
BR112021023881A2 true BR112021023881A2 (pt) 2022-02-15

Family

ID=73553925

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021023881A BR112021023881A2 (pt) 2019-05-29 2020-05-28 Métodos e composições para tratamento de epilepsia

Country Status (10)

Country Link
US (1) US20220226508A1 (pt)
EP (1) EP3976187A4 (pt)
JP (1) JP2022535744A (pt)
KR (1) KR20220015413A (pt)
CN (1) CN114007692A (pt)
AU (1) AU2020284577A1 (pt)
BR (1) BR112021023881A2 (pt)
CA (1) CA3141688A1 (pt)
EA (1) EA202193302A1 (pt)
WO (1) WO2020243349A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102580852B1 (ko) * 2021-04-13 2023-09-20 강원대학교 산학협력단 발리다마이신 a를 포함하는 뇌전증 완화 및 치료용 조성물
WO2023060024A1 (en) * 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders
CN117143993A (zh) * 2023-10-09 2023-12-01 山东省科学院生物研究所 一种基因标志物在抗癫痫药物筛选中的应用、酒石酸长春瑞滨在制备抗癫痫药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19900673A1 (de) * 1999-01-11 2000-07-13 Basf Ag Verwendung von Bindungspartnern für 5-HT5-Rezeptoren zur Behandlung neurodegenerativer und neuropsychiatrischer Störungen
BR112017018297B1 (pt) * 2015-02-25 2023-12-05 The Regents Of The University Of California Uso de um agonista de receptor 5ht selecionado a partir de trazodona e lorcarserina, ou um sal farmaceuticamente aceitável dos mesmos, e uso de um agonista de receptor 5ht selecionado a partir de clemizol, um análogo de clemizol ou um sal farmaceuticamente aceitável dos mesmos
CA3007673A1 (en) * 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same

Also Published As

Publication number Publication date
CN114007692A (zh) 2022-02-01
EA202193302A1 (ru) 2022-03-01
AU2020284577A1 (en) 2021-12-16
US20220226508A1 (en) 2022-07-21
CA3141688A1 (en) 2020-12-03
WO2020243349A1 (en) 2020-12-03
EP3976187A4 (en) 2023-08-02
JP2022535744A (ja) 2022-08-10
EP3976187A1 (en) 2022-04-06
KR20220015413A (ko) 2022-02-08

Similar Documents

Publication Publication Date Title
BR112021023881A2 (pt) Métodos e composições para tratamento de epilepsia
Merritt et al. Heightened muscle inflammation susceptibility may impair regenerative capacity in aging humans
BR112017017076A2 (pt) inibidor de il-18, anticorpo, métodos para o tratamento de uma doença ou um distúrbio associado a il-18 em um indivíduo, para determinar a quantidade de il-18 livre em uma amostra ou in situ, para diagnosticar uma predisposição a uma doença ou um distúrbio associado a il-18, para monitorar doença residual mínima em um paciente que segue o tratamento com o inibidor de il-18 ou a composição e para prever uma resposta de um paciente a um tratamento com o inibidor de il-18 ou composição, e, kit diagnóstico para detectar il-18 livre.
BR112018008746A2 (pt) composições e métodos para a inibição de atividade de arginase
JO3597B1 (ar) توليفة من عوامل تخلُّق متوالي ومركبات ثنائية النوعية تستهدفcd33 و cd3 في علاج ابيضاض الدم النقوي
BR112017010481A2 (pt) agonista parcial de receptor de insulina, composição, dímeros de análogo de insulina e de insulina, método para tratar diabetes, usos de um agonista parcial de receptor de insulina e de um composto, e, composto.
BR112012012131A2 (pt) uso de agonistas de receptores adrenérgicos alfa-2 para tratar ou prevenir psoríase
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
BR112018017168A2 (pt) emplastro de coloração do sangue, método e dispositivo para teste sanguíneo usando o mesmo
BRPI0921687A8 (pt) Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
BR112013002484A2 (pt) composto, composição farmacêutica, métodos para tratar esclerose múltipla e artrite reumatoide, e, uso de um composto.
BR112016029492A2 (pt) método para tratamento de linfoma não hodgkin
AR065589A1 (es) Prediccion de respuesta a un inhibidor her
BR112018001297A2 (pt) composição fotocrômica curável e artigo fotocrômico
BRPI0914859A2 (pt) método para diagnosticar um distúrbio afetivo, produto de programa de computador, computador, e, método para determinar uma probabilidade de que um indivíduo de teste exiba um sintoma de um distúrbio afetivo
BR112013003590A2 (pt) método de ativar células t regulatórias com agonistas de receptoe adrenérgico alfa-2b
Andrews et al. Shear stress-induced NO production is dependent on ATP autocrine signaling and capacitative calcium entry
BR112016014244A8 (pt) métodos in vitro para quantificar o nível de estresse crônico em um peixe, uso de escamas de peixe e uso de uma espinha, um raio de nadadeira ou um otólito
BR112016019740A2 (pt) monitoramento do estado de inflamação
BR112015004507A2 (pt) toner, aparelho de formação de imagem, método de formação de imagem, cartucho de processo e revelador de dois componentes
BR112012021411A2 (pt) mutações braf que conferem resistência a inibidores braf.
AR074450A1 (es) Metodos y usos que implican la proteina 1 de union a hemo
PH12017502114A1 (en) Coating agent and medical instrument surface treated with coating agent
BR112014009647A2 (pt) aparelho e método de atenuação do ruído, atenuação do ruído, e, produto de programa de computador
BR112014009338A2 (pt) aparelho de atenuação de ruído; método de atenuação de ruído; e produto de programa de computador

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]